U.S. Supreme Court to take up nursing home arbitration case

The validity of arbitration clauses in nursing home residency agreements will be decided by the U.S. Supreme Court, as justices have agreed to hear a case against two Kentucky facilities.

According to the Courthouse News Service, Extendicare and Kindred Nursing Centers, the parent companies of the nursing homes being sued, had patients’ legal representatives sign agreements that specified claims against the nursing home would be decided by arbitration, not in the courts. The companies tried to exercise this clause when sued by several patients' families for personal injuries and wrongful death, but several courts, including the Kentucky Supreme Court, ruled against them. 

“The authority to enter into a pre-dispute arbitration agreement was not among the powers granted to respective attorney-in-fact and, therefore the arbitration agreements were not formed with the assent of the party to be bound thereby,” the Court’s ruling said. "Lacking the essential element of assent, we conclude that the arbitration agreements in those cases were never validly formed.”

It could be one of several court battles brewing over mandatory arbitration agreements in nursing homes. After CMS finalized a new long-term care rule banning those clauses in future agreements, nursing homes’ top trade group filed a lawsuit seeking to block that provision from going into effect on Nov. 28.

For more on the Kentucky case and the legal argument from nursing homes, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.